Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2020 Jul 9;26(10):1876–1885. doi: 10.1016/j.bbmt.2020.07.005

Figure 2.

Figure 2.

A. Baseline (pre-ixazomib) BAFF levels in phase II patients with no chronic GVHD vs. with chronic GVHD B. Pre- and post-ixazomib BAFF levels in phase II patients with no chronic GVHD C. Pre- and post-ixazomib BAFF levels in phase II patients with chronic D. Post-ixazomib BAFF levels in phase II patients with no chronic GVHD vs. with chronic GVHD E. Pre- and post-ixazomib BAFF: B cell ratio levels in phase II patients with chronic GVHD F. Pre- and post-ixazomib BAFF: B cell ratio levels in phase II patients with no chronic GVHD G. Pre- and post-ixazomib Tregs in phase II patients with no chronic GVHD H. Pre- and post-ixazomib Tregs in phase II patients developing chronic GVHD